Traders should watch for topline data in late Q3 2026 and the ACTRIMS-ECTRIMS presentation in October 2026. Positive results could drive a re-rating given the limited treatment options for na-SPMS and the novel mechanism. Monitor for any safety signals or early efficacy trends from the OLE data.
Price Chart
Executive Summary
Tiziana Life Sciences announced completion of patient enrollment in its Phase 2a INFORM-MS trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 2026, with presentation at the ACTRIMS-ECTRIMS meeting in October 2026. This milestone de-risks the program and brings the company closer to a pivotal readout for a novel, non-invasive anti-CD3 therapy.
Key Facts
- Completed enrollment of 48 patients in Phase 2a randomized, double-blind, placebo-controlled trial (INFORM-MS) of intranasal foralumab for na-SPMS.
- Topline data expected in late Q3 2026; results to be presented at ACTRIMS-ECTRIMS meeting in Toronto, October 2026.
- Trial includes 12-week blinded treatment period followed by a 6-month open-label extension for all participants.
- Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, targeting neuroinflammation via a novel non-invasive route.
- Prior open-label Expanded Access Program (n=14) showed improvement or stability in all patients within 6 months.
Financial Impact
No financial data provided; clinical milestone with potential to unlock significant value if topline data is positive. Market cap ~$205M.
Risk Factors
- Phase 2a trial may fail to meet primary or secondary endpoints, leading to significant downside.
- Competition from existing and emerging SPMS therapies (e.g., siponimod, ocrelizumab).
- Regulatory and manufacturing risks for intranasal biologic delivery.
- Company is pre-revenue with no approved products; relies on capital markets for funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299520 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8823 (−12.64%) |
Oct 16, 2026 10d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8823 (+12.64%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8823 (−15.97%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8823 (−20.51%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 $0.8850 | ▼ −9.69% | ▼ −9.66% | $0.8823 (−9.97%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8823 (−2.47%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8823 (−9.04%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8823 (−9.04%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8823 (−23.28%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8823 (−9.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers